LAC+USC Medical Center
Public Reporting of Outcomes
Treatment of Lung Cancer at LAC+USC Medical Center

Treatment of patients with mediastinal lymph node positive disease

- For patients with non small cell lung cancer, clinically positive lymph nodes in the mediastinum (N2), should not be resected as primary therapy (NCCN v2. 2017).
- The COC standard is 85%.
- LAC+USC Medical Center continues to exceed this standard in 2014 and 2015.

Timeliness of administration of systemic therapy in patients with non small cell lung cancer

- Some patients that have had all of their disease recovered by surgery should get chemotherapy (NCCN v2. 2017).
- The Commission on Cancer’s standard is to give this adjuvant therapy within 4 months prior to surgery or 6 months after surgery. The compliance standard for CoC institutions is 85%.
- LAC+USC Medical Center and clinics continue to meet or exceed this standard in 2014 and 2015.

<table>
<thead>
<tr>
<th>Select Measures</th>
<th>Measure</th>
<th>CoC Std / %</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic chemotherapy is administered within 4 months to day preoperatively or day of surgery to 6 months postoperatively, or it is recommended for surgically resected cases with pathologic lymph node-positive (pN1) and (pN2) NSCLC (Quality Improvement)</td>
<td>LCT</td>
<td>4.5 / 85%</td>
<td>no data</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>LCT</td>
</tr>
<tr>
<td>Surgery is not the first course of treatment for cT2, M0 lung cases (Quality Improvement)</td>
<td>LNoSurg</td>
<td>4.5 / 85%</td>
<td>100.00</td>
<td>100.00</td>
<td>100.00</td>
<td>85.70</td>
<td>LNoSurg</td>
</tr>
</tbody>
</table>

Posted on LAC+USC website [http://lacusc.org](http://lacusc.org)